Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 22, 2014

Evaluation of Calfast® immunochromatographic quantitative assay for the measurement of calprotectin in faeces

Nacer Adam Benahmed, Dieudonné Manéné, Laurence Barbot-Trystram and Nathalie Kapel

Corresponding author: Nathalie Kapel, Laboratoire de Coprologie Fonctionnelle, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital, 75013 Paris, France, Phone: +33 1 42162652, Fax: +33 1 42162654, E-mail:


We would like to thank Eurospital Laboratories for providing us with the point-of-care kits.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.


1. Striz I, Trebichavsky I. Calprotectin: a pleitopric molecule in acute and chronic inflammation. Physiol Res 2004;53:245–53.Search in Google Scholar

2. Ton H, Brandsnes DS, Holtlund J, Skuibina E, Schjonsby H, Johne B. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.10.1016/S0009-8981(99)00206-5Search in Google Scholar

3. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010;15; 341:c3369.10.1136/bmj.c3369Search in Google Scholar

4. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2013 May 14, [Epub ahead of print]. Doi: 10.1038/ajg.2013.131.10.1038/ajg.2013.131Search in Google Scholar

5. Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012;45:552–5.10.1016/j.clinbiochem.2011.10.015Search in Google Scholar

6. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343–7.10.1080/00365510701576198Search in Google Scholar

7. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue(R) rapid test for faecal calprotectin. Ann Clin Biochem 2011;49:55–8.10.1258/acb.2011.011106Search in Google Scholar

8. Hessels J, Douw G, Yildirim DD, Meerman G, van Herwaarden MA, van den Bergh FA. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. Clin Chem Lab Med 2012;50:1079–82.10.1515/cclm-2011-0855Search in Google Scholar

9. Dolci A, Panteghini M. Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin. Clin Chim Acta 2012;413:350–1.10.1016/j.cca.2011.09.030Search in Google Scholar

10. Rodriguez-Otero P, Porcher R, Peffault de Latour R, Contreras M, Bouhnik Y, Xhaard A, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 2012;119:5909–17.10.1182/blood-2011-12-397968Search in Google Scholar

Received: 2014-1-6
Accepted: 2014-1-31
Published Online: 2014-2-22
Published in Print: 2014-7-1

©2014 by Walter de Gruyter Berlin/Boston